Paul L Berns insider trades: Lyell Immunopharma (LYEL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Paul reports to the SEC
and 8 more companies
Open-market buys and sales
44 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | LYEL | ↑ Buy | 2,321,262 | $10.77 | $25.0M | Indirect | Nov 5, 2026 (1d) |
| Nov 2, 2026 | ASPE | ↑ Buy | 1,200,000 | $15.00 | $18.0M | Direct | Nov 2, 2026 (0d) |
| Jun 22, 2026 | KARD | ↑ Buy | 1,250,000 | $16.00 | $20.0M | By ARCH Venture Fund XIII, L.P. | Jun 24, 2026 (2d) |
| Mar 6, 2026 | LYEL | ↑ Buy | 488,090 | $25.61 | $12.5M | Indirect | Mar 9, 2026 (3d) |
| Feb 17, 2026 | NMRA | ↓ Sell | 9,819 | $3.51 | $34K | Direct | Feb 19, 2026 (2d) |
| Feb 18, 2025 | NMRA | ↓ Sell | 13,871 | $1.69 | $23K | Direct | Feb 20, 2025 (2d) |
| Feb 3, 2025 | MTSR | ↑ Buy | 789,998 | $18.00 | $14.2M | Indirect | Feb 3, 2025 (0d) |
| Aug 5, 2021 | JAZZ | ↓ Sell | 1,450 | $154.00 | $223K | Direct | Aug 9, 2021 (4d) |
| Nov 4, 2020 | JAZZ | ↓ Sell | 4,691 | $150.42 | $706K | Direct | Nov 4, 2020 (0d) |
| Aug 7, 2020 | JAZZ | ↓ Sell | 931 | $125.87 | $117K | Direct | Aug 10, 2020 (3d) |
| Aug 9, 2019 | JAZZ | ↓ Sell | 726 | $135.65 | $98K | Direct | Aug 12, 2019 (3d) |
| Aug 10, 2018 | JAZZ | ↓ Sell | 660 | $176.61 | $117K | Direct | Aug 13, 2018 (3d) |
| Aug 11, 2017 | JAZZ | ↓ Sell | 662 | $142.37 | $94K | Direct | Aug 14, 2017 (3d) |
| Aug 15, 2016 | JAZZ | ↓ Sell | 633 | $136.45 | $86K | Direct | Aug 17, 2016 (2d) |
| Apr 20, 2016 | CLRB | ↑ Buy | 117,371 | $2.12 | $249K | Direct | Apr 21, 2016 (1d) |
| Mar 22, 2016 | ANAC | ↓ Sell | 37,500 | $60.31 | $2.3M | Direct | Mar 22, 2016 (0d) |
| Jan 4, 2016 | ANAC | ↓ Sell | 2,533 | $112.35 | $285K | Direct | Jan 5, 2016 (1d) |
| Dec 11, 2015 | ANAC | ↓ Sell | 20,000 | $117.26 | $2.3M | Direct | Dec 15, 2015 (4d) |
| Sep 15, 2015 | ANAC | ↓ Sell | 20,000 | $139.83 | $2.8M | Direct | Sep 17, 2015 (2d) |
| Aug 13, 2015 | ANAC | ↓ Sell | 20,000 | $138.69 | $2.8M | Direct | Aug 17, 2015 (4d) |
| Aug 10, 2015 | JAZZ | ↓ Sell | 801 | $180.00 | $144K | Direct | Aug 11, 2015 (1d) |
| Apr 27, 2015 | ANAC | ↓ Sell | 50,000 | $63.64 | $3.2M | Direct | Apr 28, 2015 (1d) |
| Mar 19, 2015 | ANAC | ↓ Sell | 37,500 | $56.07 | $2.1M | Direct | Mar 23, 2015 (4d) |
| Dec 26, 2014 | ANAC | ↓ Sell | 25,000 | $30.82 | $771K | Direct | Dec 29, 2014 (3d) |
| Aug 12, 2014 | JAZZ | ↓ Sell | 1,087 | $133.15 | $145K | Direct | Aug 14, 2014 (2d) |
| May 15, 2014 | XNPT | ↓ Sell | 2,500 | $3.66 | $9K | Direct | May 16, 2014 (1d) |
| Apr 24, 2014 | XNPT | ↓ Sell | 2,500 | $4.30 | $11K | Direct | Apr 24, 2014 (0d) |
| Aug 13, 2013 | JAZZ | ↓ Sell | 1,070 | $81.86 | $88K | Direct | Aug 14, 2013 (1d) |
| Mar 9, 2012 | JAZZ | ↓ Sell | 39,200 | $49.56 | $1.9M | Direct | Mar 13, 2012 (4d) |
| Mar 1, 2012 | ALTH | ↓ Sell10b5-1 | 42,695 | $1.50 | $64K | Direct | Mar 1, 2012 (0d) |
| Feb 24, 2012 | ALTH | ↓ Sell10b5-1 | 13,450 | $1.56 | $21K | Direct | Feb 27, 2012 (3d) |
| Nov 16, 2011 | ALTH | ↓ Sell10b5-1 | 32,267 | $1.46 | $47K | Direct | Nov 17, 2011 (1d) |
| Feb 24, 2011 | ALTH | ↓ Sell10b5-1 | 13,448 | $3.21 | $43K | Direct | Feb 25, 2011 (1d) |
| Feb 24, 2010 | ALTH | ↓ Sell10b5-1 | 11,666 | $7.55 | $88K | Direct | Feb 24, 2010 (0d) |
| Feb 8, 2010 | ALTH | ↓ Sell10b5-1 | 32,580 | $7.00 | $228K | Direct | Feb 10, 2010 (2d) |
| Jan 8, 2010 | ALTH | ↓ Sell10b5-1 | 65,160 | $7.00 | $456K | Direct | Jan 12, 2010 (4d) |
| Aug 10, 2009 | ALTH | ↓ Sell10b5-1 | 342,000 | $8.24 | $2.8M | Direct | Aug 12, 2009 (2d) |
| Aug 5, 2009 | ALTH | ↓ Sell10b5-1 | 8,000 | $8.14 | $65K | Direct | Aug 7, 2009 (2d) |
| Jun 16, 2008 | XNPT | ↓ Sell10b5-1 | 12,500 | $42.02 | $525K | Direct | Jun 17, 2008 (1d) |
| Mar 10, 2008 | ALTH | ↓ Sell10b5-1 | 34,400 | $5.38 | $185K | Direct | Mar 12, 2008 (2d) |
| Dec 31, 2007 | ALTH | ↑ Buy | 5,000 | $3.89 | $19K | Direct | Jan 3, 2008 (3d) |
| Mar 12, 2007 | ALTH | ↓ Sell10b5-1 | 23,625 | $6.45 | $152K | Direct | Mar 14, 2007 (2d) |
| Dec 29, 2006 | ALTH | ↑ Buy | 2,500 | $3.05 | $8K | Direct | Jan 3, 2007 (5d) |
| Apr 13, 2006 | ALTH | ↑ Buy | 5,000 | $2.94 | $15K | Direct | Apr 17, 2006 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LYEL insiders
Open-market trades in the last 12 months
About Paul L Berns's insider trades
Paul L Berns is a 10% owner of Lyell Immunopharma (LYEL). Since Apr 13, 2006, Paul has reported 9 open-market purchases worth $90.0M and 35 sales worth $25.1M on SEC Form 4. In the last 12 months: 4 buys ($75.5M) and 1 sale ($34K).
12 sales (19% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (57 filings), option exercises (13 filings), shares returned to the company (10 filings), conversions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.